Mitofusin Inhibitor Composition for Stem Cell Reprogramming Efficiency

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for reprogramming differentiated cells into pluripotent stem cells face inefficiencies and challenges in maintaining pluripotency, particularly due to the limitations of p53 and mitochondrial dynamics, which affect cell cycle progression and metabolic reprogramming.

Innovation Solution

The use of a composition comprising a repressor of mitofusin gene expression or an inhibitor of mitofusin protein activity to promote dedifferentiation and maintain pluripotency, including the use of antisense oligonucleotides, siRNA, shRNA, or specific compounds like tetramethylpyrazine and U74389G maleate to downregulate mitofusin activity, facilitating a shift from mitochondrial to glycolytic metabolism.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional reprogramming methods are used to reprogram differentiated cells into pluripotent stem cells, then reprogramming can occur, but the reprogramming efficiency is low and the process is time-consuming

Engineering Contradiction:
Improvereprogramming efficiencyVSAvoidreprogramming time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The invention extracts and removes the limiting factor (mitofusin protein) that prevents efficient reprogramming. By using specific inhibitors to block mitofusin activity, the patent removes the mitochondrial fusion barrier that normally constrains reprogramming efficiency, allowing cells to transition to pluripotency much more rapidly and efficiently.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the metabolic state parameter of the cells by inhibiting mitofusin, which shifts cells from oxidative phosphorylation to glycolysis. This parameter change in metabolic mode creates a permissive state for rapid reprogramming, transforming the cellular environment to favor pluripotency acquisition.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If p53 pathway is active to maintain genome stability, then cell cycle arrest and senescence occur to protect against reprogramming-induced stress, but this limits cell fate transition and reduces reprogramming efficiency

Engineering Contradiction:
Improvegenome stabilityVSAvoidreprogramming efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The invention converts the harmful effect of active p53 (which blocks reprogramming) into a benefit by using mitofusin inhibition to indirectly suppress p53 activity. The mitofusin inhibitor creates a metabolic shift that leads to reduced p53-mediated cell cycle arrest, allowing efficient reprogramming while maintaining genome stability through alternative mechanisms.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Stability of the object's composition

If mitofusin activity is maintained to support mitochondrial ATP production, then cellular homeostasis is maintained, but reprogramming efficiency is reduced and pluripotency maintenance is impaired

Engineering Contradiction:
Improvecellular homeostasisVSAvoidreprogramming efficiency
Core Design Contradiction:
Stability of the object's compositionVSProductivity

Solution Approach 1:

The invention introduces dynamic control of mitochondrial function by temporarily inhibiting mitofusin during the reprogramming process. This dynamic approach allows the system to switch from a stable mitochondrial state to a plastic metabolic state conducive to reprogramming, and then potentially restore homeostasis in the pluripotent state.

Inventive Principle:
Principle #15Dynamics

Solution Approach 2:

The invention changes the metabolic parameter from oxidative phosphorylation to glycolysis by inhibiting mitofusin. This parameter change creates the metabolic flexibility needed for reprogramming while maintaining cellular homeostasis through alternative energy pathways.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP3041928B1Compositions comprising a mitofusin inhibitor for promoting cell reprogramming and a use thereof
Publication Date: 2020.03.25 KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY
  • EP3041928B1 patent drawingFigure 1a~1b
  • EP3041928B1 patent drawingFigure 1c~1d
  • EP3041928B1 patent drawingFigure 1e

AI summary

The present invention relates to a composition comprising a repressor of mitofusin gene expression, an inhibitor of mitofusin protein activity, or a mixture thereof as an active ingredient for promoting reprogramming a differentiated cell into a pluripotent stem cell, and a use thereof. The composition according to the present invention increases the efficiency of reprogramming as well as reduces the time required for reprogramming to produce pluripotent stem cells. Therefore, the present composition can be beneficially used to develop the production technology of high efficiency pluripotent stem cell and secure a large-scale culture system. Further, the present composition can be beneficially used to maintain pluripotent stem cells and screen the compounds capable of promoting the reprogramming into pluripotent stem cells.